

Recovery Rate and Hospitalization stay patient Treated with Corticosteroids alone, along with Antiviral Oral and Intravenous - Faviparavir&Remdesivir - 40 Patients Clinical study

Mayank Chugh¹, Satender Tanwar²

Author Affiliation

¹Gastroenterologist, ²Associate Consultant, Chugh Multispecialty Hospital, Bhiwani, Haryana 121013, India

Corresponding Author

Satender Tanwar - Associate Consultant, Chugh Multispecialty Hospital, Bhiwani, Haryana. 121013, India
E-mail: chughmayank@gmail.com

Abstract

Corona Virus disease led to large devastating and other complication from root to the periphery¹. Various complications has been acknowledged during the pandemic so far such as raised glycemic index, long term lung fibrosis and other complications such as Mucormycosis.

The various treatment modalities has been encounter so far which are as usual led to some or more beneficial effect and recovery of the patients. The corticosteroids being the most important remedy later proved to the disease enhancement and complication. In the similar way the antiviral drugs used are either Oral and intravenous not caused much of reduction in the mortality and hospitalization stay. As per the current data and the statistics no proven drugs antiviral has been used for the SARS COVID 19, the used one which are as Favipiravir, remdesivir and Mechanical ventilation².

In this present study the 40 patient given treatment in three groups made treated with Corticosteroids alone, along with Antiviral Oral and Intravenous - Favipiravir & Remdesivir. After analyzing the data is found that none of the antiviral has made significant reduction in the hospitalization stay treated at IPD of chugh Multispecialty Hospital. Thus concluded that patient treated along with corticosteroids along with Antiviral oral and intravenous doesn't make any significant changes in the hospital stay.

Key Words: COVID, Pandemic, Antiviral, Oral, Intravenous, Corticosteroids, Favipiravir and Remdesivir.

How to cite this article:

Mayank Chugh, Satender Tanwar, Recovery Rate and Hospitalization stay patient Treated with Corticosteroids alone, along with Antiviral Oral and Intravenous - Faviparavir&Remdesivir - 40 Patients Clinical study. *Gastroenterology International*. 2018;3(1-2):5-11.

Introduction

Corona Virus disease which is being causing the wide varieties of the complication and spread through the droplet, oral, hand and air borne infection. People are getting usually infected by the

spread of virus through the contaminated articles, air borne infection³.

Mostly people doesn't require the hospitalization and recover even without any treatment and hospitalization⁴. Usually Found symptoms are such as fever, cough, myalgia, chest pain and

Tiredness. For wide varieties of modalities which are being made for the needful, as per looking in to the data and drugs used which are suggestive of the antiviral properties such as Favipiravir and remdesivir.

Favipiravir is the widely used drug for the covid 19 which has been observed as good evaluation and effective as placebo effect when compared with the other data and statistics. The extra added side effects of the known drugs has been used and evaluated for needful, in the present study no added benefitted effect has been observed in case of the Favipiravir and Remdesivir⁵.

The Randomised COVID-19 Therapy (RECOVERY) trial, a multicenter, randomized, open-label trial in hospitalized patients with COVID-19, showed that the mortality from COVID-19 was lower among patients who were randomized to receive dexamethasone than among those who treated with the standard of care.⁶ In SARS covid 19 the efficacy and statistics which has been used are alarming for the comparison done for the antiviral therapy⁷.

However, the combination of the therapy which has been used found to be the deleterious effect and used to be very cautiously Corticosteroids has been used for the patients who are sick and need of increased oxygen demands⁸.

Seven randomized controlled trials suggested that corticosteroids are found effective in the severe cases of the SARS COVID 19 Remdesivir- the dosage of the antiviral drug Remdesivir, being administered to hospitalized COVID-19 patients from the earlier six-days to five-day treatment.

According to the Health Ministry, remdesivir drug is only for restricted emergency use used with the patients those who require the oxygen therapy and increasing demands of the oxygen.

Also, the line of treatment which are been used for the effective case therapy in many cases and used , Remdesivir and Favipiravir . The Corticosteroids which are found to be effective needful infection⁹.

Favipiravir is the drug which we are using are the against replication of RNA of the virus and found to be effective at certain levels¹⁰. In view of recent studies and discussion on favipiravir, in this mini review we aimed to summarize the clinical trials studying the efficacy and safety of favipiravir in patients with COVID-19¹¹.

Data Collected - Sr No _GROUP A _GROUP B _ GROUP C _ _ _CORTICOSTEROIDS _ FAVIPIRIVIR _REMIDESIVIR _ _ _20 Patients _10 Patients _10 Patients _ _ Observations- Following Data has been collected and observations has been made such as out of 40 patients studied total, 20 patients on corticosteroids and 10 has been treated with Favipiravir and remaining 10 has been treated with Remdesivir.

Conclusions

The patients treated on Corticosteroids, favipiravir and Remdesivir as stated above has been analyzed and found that there were much significant statistical variation in the patients treated with above drugs either in the hospitalization and symptoms such as fever, cough, and respiratory distress¹³. The study may need to be conducted on large group of sample size for further understanding and variables.

References

1. Abd-Elsalam S, Esmail ES, Khalaf M et al (2020) Tanta protocol for management of COVID-19. Perspectives from a developing country. *Endocr Metab Immune Disord Drug Targets*. <https://doi.org/10.2174/1871530320999201117142305>.
2. Xie M, Chen Q (2020) Insight into 2019 novel coronavirus – an updated interim review and lessons from SARS-CoV and MERS-CoV. *Int J Infect Dis*. <https://doi.org/10.1016/j.ijid.2020.03.071> Marjot T, Moon AM, Cook JA et al (2020) Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. *J Hepatol*. <https://doi.org/10.1016/j.jhep.2020.09.024>
3. Cai Q, Yang M, Liu D et al (2020) Experimental treatment with favipiravir for COVID-19: an open-label control study. *Engineering (Beijing)*. <https://doi.org/10.1016/j.eng.2020.03.007>.
4. Faul F, Erdfelder E, Lang A-G et al (2007) A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. *Behav Res Methods* 39:175-191
5. World Health Organization. Coronavirus disease (COVID-19) situation report – 139. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200607-covid-19-sitrep-139.pdf?sfvrsn=79dc6d08_2. Accessed 8 June 2020.
6. Oestereich L, Lüdtkke A, Wurr S et al (2014) Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. *Antiviral Res* 105:17-21

7. Madelain V, Oestereich L, Graw F et al (2015) Ebola virus dynamics in mice treated with favipiravir. *Antiviral Res* 123:70-77
8. Noda A, Shirai T, Nakajima H et al (2020) Case report: two cases of COVID-19 pneumonia including use of favipiravir. *The Japanese Association for Infectious Diseases*. http://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_en_200408_2.pdf
9. Yokoyama K, Oguri T, Kato A et al (2020) Case report a case of COVID-19 pneumonia that did not worsen and was relieved by early administration of favipiravir and ciclesonide. http://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_en_200406.pdf.
10. Abena PM et al (2020) Chloroquine and hydroxychloroquine for the prevention or treatment of COVID-19 in Africa: caution for inappropriate off-label use in healthcare settings. *Am J Trop Med Hyg* 102:1184-1188
11. Furuta Y et al (2005) Mechanism of action of T-705 against influenza virus. *Antimicrob Agents Chemother*. 49:981-986
12. Irie K, Nakagawa A, Fujita H et al (2020) Pharmacokinetics of favipiravir in critically ill patients with COVID-19. *ClinTransl Sci*. 13(5):880-885
13. Doi K, Ikeda M, Hayase N et al (2020) Nafamostatmesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series. *Crit Care* 24:39.
